Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Toxicology Drug Screening Market Outlook (2023 to 2033)

The global toxicology drug screening market is anticipated to reach US$ 70.80 billion by 2033, up from US$ 25.99 billion in 2023 advancing at a rapid CAGR of 10.5% during the forecast period. The demand for toxicology drug screening is on the surge as toxicology screening process can be done very quickly and provides approximate results showing the presence of specific drug in the system.

Toxicological screening is done for four primary purposes that includes medical testing, employment drug testing, forensic analysis, and athletics testing and the adoption of the same rises as it enables control in consumption of illegal drugs.

A doctor or physician performs a toxicology screen in case of accidents or sexual assaults on a person if suspected with the drug intoxication or overdose symptoms including unconsciousness, panic attacks, chest pain, deliriousness, and seizures. Furthermore, the toxicology drug screening market growth is fostered by its use before undergoing an organ transplant, drug abuse, during pregnancy.

Attributes Details
Historical Value (2022) US$ 23.88 billion
Current Year Value (2023) US$ 25.99 billion
Expected Forecast Value (2033) US$ 70.80 billion
Historical CAGR (2018 to 2022) 8.8%
Projected CAGR (2023 to 2033) 10.5%

Toxicology drug screening find vast applications in food and beverage industries, chemical industries, cosmetics and households and pharmaceutical companies which augments the adoption of toxicology drug screening.

These screening tests are majorly intended for detection of illegal drugs in victim’s blood or urine sample. Biochemical assays, cellular assays, reagents and kits, in silico services are the major type of toxicological drug screening products available in the industry.

Many of these screening tests are performed to determine systemic toxicity, carcinogenicity, dermal toxicity, genotoxicity, neurotoxicity, and organ-specific toxicity and thus contribute majorly to the revenue generation in toxicology drug screening market.

The toxicology drug screening market outlook is swayed by these toxicology drug screening methods as they are performed using various high-end technologies such as high-throughput screening, genomics, transcriptomics, and molecular screening.

The increasing usage of toxicological screening generates large revenues in the toxicology drug screening market owing to their growing demand in hospitals and trauma centers, rehabilitation centers and forensic laboratories.

Increasing adoption of in-vitro methods to detect toxic drugs in human system tends to propel the growth of toxicology drug screening market across the globe and registers a significant revenue growth in the toxicology drug screening market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What Factors are Spearheading the Toxicology Drug Screening Market?

Growing technological advancements leading to development of novel screening products are majorly contributing to the rising adoption of toxicology drug screening worldwide. Moreover, increasing availability of high-end drug screening instruments, reagent and kits coupled with wide application areas for toxicology drug screening are also expected to drive the growth of toxicology drug screening market.

Introduction of rapid and automated toxicity detection technologies, increasing government expenditure on toxicity testing and favorable reimbursement policies in toxicity screening is further fostering the toxicology drug screening market. Also, rise in demand for toxicology drug screening in the food and beverage industry, and chemical industry is also expected to drive the overall market growth.

However, inadequate efficacy of conventional techniques and longer time taken by laboratories for sample testing are some of the factors restraining the toxicology drug screening market during the forecast period.

Regional Analysis

Regions 2022 Value Share in Global Market
North America 43.1%
Europe 32.3%

What Factors Contribute to the North America’s Leading Position in the Toxicology Drug Screening Market?

On account of the expanding research and development activities in this area to detect toxicity levels in the human body at early stages, North America held a market share of 43.1% in 2022. As these trials are being outsourced to other locations, such as Asia, research and development in this region has hit a plateau.

In addition, pharmaceutical companies' R&D expenses have increased in recent years, owing to the increasing burden of diseases, therapy sectors, and complex compounds, expanding the toxicology drug screening market size in the region.

What are the Growth Prospects for the Europe Toxicology Drug Screening Market?

Europe had a 32.3% market share in toxicological drug screening in 2022 primarily due to growing R&D activities to detect toxicity levels in the human body at early stages.

Regulatory approvals, new products, and product launches are projected to drive the growth of the Europe drug screening market during the forecast period.

Furthermore, rising government financing is expected to move the European toxicology drug screening market forward.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise

Countries 2022 Value Share in Global Market
United States 41.2%
Germany 6.8%
Japan 3.5%

How Are Point-of-care Toxicology Tests Revolutionizing Drug Screening in the United States?

The United States toxicology drug screening market has experienced significant growth in recent years, driven by factors such as

  • increasing drug abuse
  • stringent government regulations
  • the need for workplace safety
  • the country is facing a severe opioid crisis

The United States has the maximum drug abuse rates globally, resulting in a high demand for toxicology drug screening tests. This country has an increasing trend of embracing point-of-care toxicology drug screening tests. These tests are gaining popularity in emergency departments, rehabilitation centers, and workplaces. The reason behind their popularity lies in their ability to provide rapid results, convenience, and cost-effectiveness.

Workplace substance use is regulated by various federal requirements, including the Drug-Free Workplace Act of 1988, which specifically addresses this issue. These laws mandate certain employers to implement measures against drug use in the workplace, such as the development of a written policy.

What Factors are Driving the Demand for Toxicology Drug Screening in Germany?

Traditional drug screening methods are being replaced by advanced technologies such as liquid chromatography-mass spectrometry (LC-MS) and immunoassays. These methods offer higher accuracy and sensitivity, thereby boosting their adoption in the Germany toxicology drug screening market. Germany is facing a growing concern regarding substance abuse, including illegal drugs and prescription medications. This has further fueled the need for toxicology drug screening to identify and address drug-related issues.

In Germany, there is no clear or particular legislation governing drug tests. The basic principles and legislative regulations on the collecting and use of health-related data are applicable to drug testing during the pre-employment stage and at the workplace. According to the Federal Data Protection Act's section 4 subsection, the subject must be notified about the data that is going to be collected. The law's guidelines must be followed if the data must be maintained after collection.

What Ongoing Developments are Redefining Toxicology Drug Screening in Japan?

There is a growing trend of workplace drug testing in Japan, driven by the need to maintain a safe and productive work environment. Many companies have started implementing drug testing programs to ensure the well-being of their employees and prevent substance abuse-related incidents.

Japan has a well-established healthcare system with significant healthcare expenditures. The government's focus on healthcare infrastructure development and increasing healthcare spending further supports the growth of the Japan toxicology drug screening market.

Japan has stringent regulations in place for drug testing and toxicology screening. The Ministry of Health, Labor, and Welfare (MHLW) regulates and oversees the approval process for diagnostic devices and ensures compliance with safety and quality standards. This regulatory environment creates opportunities for companies offering compliant toxicology screening solutions.

Countries Value CAGR (2023 to 2033)
United Kingdom 8.2%
China 12.8%
India 10.8%

What Makes the Regulatory Framework for Drug Screening in the United Kingdom Stand Out?

The United Kingdom has witnessed a growing emphasis on workplace drug testing due to the rising concerns regarding drug abuse in various industries. In this country, many firms have made screening a component of their drug and alcohol policies. In the past ten years, workplace drug testing has transformed from a controversial tactic viewed as an unfair ploy by employers to a legally justifiable option. Its prevalence has increased since 2014 and is now considered a standard practice in safety-critical industries. This trend is driving the United Kingdom toxicology drug screening market.

In the United Kingdom, drug testing is permitted. However, there are rules that companies must go with. Organizations conducting drug screening must adhere to guidelines and standards set by regulatory bodies such as the National Institute for Health and Care Excellence (NICE). This regulatory environment ensures the quality and reliability of drug screening services in the country.

What Factors are Driving the Rising Incidence of Drug Abuse in China?

The China toxicology drug screening market has been witnessing significant growth over the past few years. China's pharmaceutical industry has experienced substantial expansion, driven by increasing urbanization, a rising aging population, and improved healthcare infrastructure. With urbanization and social changes, drug abuse has become a significant concern in China. This has driven the demand for toxicology drug screening tests, both in workplace screening and rehabilitation centers.

China's rapid economic growth has resulted in higher healthcare spending. The government's initiatives to improve healthcare access and quality have led to increased investment in healthcare facilities and diagnostic technologies, including toxicology drug screening. The Drug Administration Law of the People's Republic of China became effective on December 1, 2019. The regulatory framework for toxicology drug screening in China is continually evolving, leading to market growth.

What Role Are Government Initiatives Playing in the Growth of the India Toxicology Drug Screening Market?

The increasing prevalence of drug abuse, stringent regulations for workplace drug testing, and the growing awareness about the adverse effects of substance abuse are driving the demand for toxicology drug screening. India's rapid economic growth and increasing disposable incomes are also fueling the demand for toxicology drug screening products and services.

India has seen a surge in substance abuse cases, including opioids, cannabis, and pharmaceutical drugs. This has created a pressing need for effective drug screening measures to identify and address drug abuse issues. The Indian government is actively working on strengthening drug abuse prevention measures. A pharmaceutical company needs the drug controller general's approval for a new prescription medicine to be sold in India.

Segment-wise Analysis

Segment 2022 Value Share in Global Market
Acute Systemic Toxicity 57.1%
Pharma and Biopharma Companies 42.7%

How Does the Acute Systemic Toxicity Test Excel in Toxicology Drug Screening?

Acute systemic toxicity testing is a crucial component of drug development and safety assessment. It involves evaluating the adverse effects of a substance when administered systemically to determine its potential toxicity. Regulatory requirements play a crucial role. Regulatory bodies such as the Food and Drug Administration in the United States and the European Medicines Agency in Europe often demand acute systemic toxicity data as part of the preclinical safety assessment for drug approval. Meeting these requirements drives the demand for this testing segment.

Acute systemic toxicity testing provides valuable insights into the potentially harmful effects of a drug or chemical on various organs and systems in the body. This information is vital in identifying and assessing potential risks during drug development and screening processes. Moreover, acute systemic toxicity testing allows for early-stage screening and comparative analysis of different compounds or formulations. Resources and effort can be saved by identifying and eliminating toxic substances in the early stages.

Why do Pharma and Biopharma Companies Outshine Others in Toxicology Drug Screening?

Pharma and biopharma companies hold a dominant position in the toxicology drug screening market for several key reasons. Firstly, these companies heavily invest in research and development activities, relying on toxicology drug screening to evaluate the safety and efficacy of their drug candidates. This demand arises from the need to comply with stringent regulatory requirements and ensure their products meet safety standards. Pharma and biopharma companies conduct comprehensive toxicology screening to assess potential adverse effects and determine optimal dosage levels. Their adherence to regulatory compliance drives the demand for toxicology screening services.

The scale and resources of these companies contribute to their dominance. They possess the financial capacity to invest in advanced screening technologies and equipment, operate well-equipped laboratories, employ expert toxicologists, and access a wide range of biological samples for testing. Their large-scale operations allow them to conduct extensive toxicology studies, consolidating their position in the market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

How is the Start-up Ecosystem in the Toxicology Drug Screening Market?

A wide array of toxicology drug screening market opportunities are opened up by the emerging start-ups in the toxicology drug screening market.

Examples:

  • Nagi Bioscience, a start-up based in Switzerland aims to revolutionise the way toxic and/or beneficial effects of substances are tested today by combining the use of microscopic worms as in vivo models for drug/chemical screening with the first technological platform for their fully automated in vitro culture, treatment, and multi-parametric analysis.

Increasing innovation and efficiency in the pharmaceutical, chemical, and cosmetic sectors, while also contributing to the replacement, refinement, and reduction of animal testing.

  • Today, the pharmaceutical business relies on the in-vitro cell-based high-content-screening (HCS) market, which was valued at $557 million in 2017, but frequently overlooks minor traits. Humanized models are a better predictor of disease pathology, but no HCS assays are available.

Newormics' first product, a microfluidic-based technology, provides fast automated phenotyping of humanised C. elegans disease models and selects leads to address the unmet demand for HCS employing humanised animal models.

What is the Competition Landscape in the Toxicology Drug Screening Market?

The toxicology drug screening market is consolidated and fairly competitive, with a few prominent competitors capturing major chunk of toxicology drug screening market share.

Some of the recent developments in the market are:

  • The Metropolitan Police Department (MPD) in Japan created the nation's first simple test kit in April 2023. This kit allows for quick determination of whether a person has consumed a "date rape drug." These drugs have a sedative effect and are often used in sexual crimes. The purpose of the test kit is to accelerate the investigation process for such offenses.
  • Marshall Health and Mountain Health Network unveiled novel drug testing services in November 2022. These services involve urine testing for drugs of abuse. They cater to employers and healthcare providers and are capable of delivering results within three business days. Employers can also avail of MHCS services for testing new employees. Furthermore, the services offer continuous monitoring to ensure compliance with state and federal laws.
  • Chief. AI, a machine learning operations platform, introduced the first no-code, pay-as-you-go artificial intelligence (AI) platform for drug development in collaboration with the Medicines Discovery Catapult.
  • Mydecine Innovations Group, an emerging biopharma and life sciences company dedicated to development, acceptance of alternative nature-sourced medicine for mainstream use, and research has announced the launch of its in-silico drug discovery programme in collaboration with researchers at the University of Alberta.

Key Players

  • Agilent Technologies, Inc.
  • Covance, Inc.
  • Bio-Rad Laboratories, Inc.
  • General Electric Company
  • BioReliance, Inc.
  • Thermo Fisher Scientific, Inc.
  • Eurofins Scientific SE
  • GE Healthcare
  • Quest Diagnostics
  • Alere, Inc.
  • Enzo Life Sciences, Inc.

Key Segments Profiled in the Toxicology Drug Screening Market Survey

By Product Type:

  • Monitoring and logging
  • Security
  • Storage and continuous integration/continuous deployment
  • Management and orchestration
  • Networking and data management services
  • Others

By Test Type:

  • Acute Systemic Toxicity
  • Dermal Toxicity
  • Carcinogenicity
  • Ocular Toxicity
  • Genotoxicity
  • Neurotoxicity
  • Organ-Specific Toxicity

By Technology Type:

  • High-Throughput Screening
  • Genomics
  • Transcriptomics
  • Toxicogenomics
  • Molecular Screening

By End Use:

  • Hospitals and Trauma Centers
  • Forensic Laboratories
  • Diagnostic Laboratories
  • Rehabilitation Centers
  • Pharmaceutical & Biotechnology Companies

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
  • Europe

Frequently Asked Questions

How Much the Toxicology Drug Screening Market is Slated to Achieve by 2033?

The market is slated to achieve US$ 70.80 billion by 2033.

What is the Scope for Growth of the Market?

The market is anticipated to expand at a CAGR of 10.5%.

Which Region Holds Monopoly in the Market?

North America holds monopoly in the market with a massive share of 43.1%.

What Factors Consolidate the Market?

The market is consolidated by surging drug abuse and strict government laws.

Which Country Exhibits Robust Growth?

China exhibits a rampant growth of 12.8% CAGR.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033

        5.3.1. Monitoring and logging

        5.3.2. Security

        5.3.3. Storage and continuous integration/continuous deployment

        5.3.4. Management and orchestration

        5.3.5. Networking and data management services

        5.3.6. Others

    5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033

        6.3.1. Acute Systemic Toxicity

        6.3.2. Dermal Toxicity

        6.3.3. Carcinogenicity

        6.3.4. Ocular Toxicity

        6.3.5. Genotoxicity

        6.3.6. Neurotoxicity

        6.3.7. Organ-Specific Toxicity

    6.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology Type 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Technology Type, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology Type, 2023 to 2033

        7.3.1. High-Throughput Screening

        7.3.2. Genomics

        7.3.3. Transcriptomics

        7.3.4. Toxicogenomics

        7.3.5. Molecular Screening

    7.4. Y-o-Y Growth Trend Analysis By Technology Type, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Technology Type, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033

        8.3.1. Hospitals and Trauma Centers

        8.3.2. Forensic Laboratories

        8.3.3. Diagnostic Laboratories

        8.3.4. Rehabilitation Centers

        8.3.5. Pharmaceutical & Biotechnology Companies

    8.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. South Asia and Pacific

        9.3.6. East Asia

        9.3.7. Middle East and Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Product Type

        10.2.3. By Test Type

        10.2.4. By Technology Type

        10.2.5. By End Use

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product Type

        10.3.3. By Test Type

        10.3.4. By Technology Type

        10.3.5. By End Use

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Product Type

        11.2.3. By Test Type

        11.2.4. By Technology Type

        11.2.5. By End Use

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product Type

        11.3.3. By Test Type

        11.3.4. By Technology Type

        11.3.5. By End Use

    11.4. Key Takeaways

12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. UK

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Western Europe

        12.2.2. By Product Type

        12.2.3. By Test Type

        12.2.4. By Technology Type

        12.2.5. By End Use

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product Type

        12.3.3. By Test Type

        12.3.4. By Technology Type

        12.3.5. By End Use

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Czech Republic

            13.2.1.4. Romania

            13.2.1.5. Rest of Eastern Europe

        13.2.2. By Product Type

        13.2.3. By Test Type

        13.2.4. By Technology Type

        13.2.5. By End Use

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Product Type

        13.3.3. By Test Type

        13.3.4. By Technology Type

        13.3.5. By End Use

    13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Bangladesh

            14.2.1.3. Australia

            14.2.1.4. New Zealand

            14.2.1.5. Rest of South Asia and Pacific

        14.2.2. By Product Type

        14.2.3. By Test Type

        14.2.4. By Technology Type

        14.2.5. By End Use

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Product Type

        14.3.3. By Test Type

        14.3.4. By Technology Type

        14.3.5. By End Use

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Product Type

        15.2.3. By Test Type

        15.2.4. By Technology Type

        15.2.5. By End Use

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Product Type

        15.3.3. By Test Type

        15.3.4. By Technology Type

        15.3.5. By End Use

    15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Product Type

        16.2.3. By Test Type

        16.2.4. By Technology Type

        16.2.5. By End Use

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Product Type

        16.3.3. By Test Type

        16.3.4. By Technology Type

        16.3.5. By End Use

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Product Type

            17.1.2.2. By Test Type

            17.1.2.3. By Technology Type

            17.1.2.4. By End Use

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Product Type

            17.2.2.2. By Test Type

            17.2.2.3. By Technology Type

            17.2.2.4. By End Use

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Product Type

            17.3.2.2. By Test Type

            17.3.2.3. By Technology Type

            17.3.2.4. By End Use

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Product Type

            17.4.2.2. By Test Type

            17.4.2.3. By Technology Type

            17.4.2.4. By End Use

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Product Type

            17.5.2.2. By Test Type

            17.5.2.3. By Technology Type

            17.5.2.4. By End Use

    17.6. UK

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Product Type

            17.6.2.2. By Test Type

            17.6.2.3. By Technology Type

            17.6.2.4. By End Use

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Product Type

            17.7.2.2. By Test Type

            17.7.2.3. By Technology Type

            17.7.2.4. By End Use

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Product Type

            17.8.2.2. By Test Type

            17.8.2.3. By Technology Type

            17.8.2.4. By End Use

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Product Type

            17.9.2.2. By Test Type

            17.9.2.3. By Technology Type

            17.9.2.4. By End Use

    17.10. Poland

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Product Type

            17.10.2.2. By Test Type

            17.10.2.3. By Technology Type

            17.10.2.4. By End Use

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Product Type

            17.11.2.2. By Test Type

            17.11.2.3. By Technology Type

            17.11.2.4. By End Use

    17.12. Czech Republic

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Product Type

            17.12.2.2. By Test Type

            17.12.2.3. By Technology Type

            17.12.2.4. By End Use

    17.13. Romania

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Product Type

            17.13.2.2. By Test Type

            17.13.2.3. By Technology Type

            17.13.2.4. By End Use

    17.14. India

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Product Type

            17.14.2.2. By Test Type

            17.14.2.3. By Technology Type

            17.14.2.4. By End Use

    17.15. Bangladesh

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Product Type

            17.15.2.2. By Test Type

            17.15.2.3. By Technology Type

            17.15.2.4. By End Use

    17.16. Australia

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Product Type

            17.16.2.2. By Test Type

            17.16.2.3. By Technology Type

            17.16.2.4. By End Use

    17.17. New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Product Type

            17.17.2.2. By Test Type

            17.17.2.3. By Technology Type

            17.17.2.4. By End Use

    17.18. China

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Product Type

            17.18.2.2. By Test Type

            17.18.2.3. By Technology Type

            17.18.2.4. By End Use

    17.19. Japan

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Product Type

            17.19.2.2. By Test Type

            17.19.2.3. By Technology Type

            17.19.2.4. By End Use

    17.20. South Korea

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Product Type

            17.20.2.2. By Test Type

            17.20.2.3. By Technology Type

            17.20.2.4. By End Use

    17.21. GCC Countries

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Product Type

            17.21.2.2. By Test Type

            17.21.2.3. By Technology Type

            17.21.2.4. By End Use

    17.22. South Africa

        17.22.1. Pricing Analysis

        17.22.2. Market Share Analysis, 2022

            17.22.2.1. By Product Type

            17.22.2.2. By Test Type

            17.22.2.3. By Technology Type

            17.22.2.4. By End Use

    17.23. Israel

        17.23.1. Pricing Analysis

        17.23.2. Market Share Analysis, 2022

            17.23.2.1. By Product Type

            17.23.2.2. By Test Type

            17.23.2.3. By Technology Type

            17.23.2.4. By End Use

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Product Type

        18.3.3. By Test Type

        18.3.4. By Technology Type

        18.3.5. By End Use

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Agilent Technologies, Inc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Covance, Inc.

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Bio-Rad Laboratories, Inc.

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. General Electric Company

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. BioReliance, Inc.

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Thermo Fisher Scientific, Inc.

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Eurofins Scientific SE

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. GE Healthcare

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Quest Diagnostics

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Alere, Inc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Enzo Life Sciences, Inc.

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Drug Discovery Services Market

Published : April 2023

Healthcare

Drug Screening Market

Published : January 2023

Explore Healthcare Insights

View Reports

Toxicology Drug Screening Market